Medtech Ireland – Galway, Global Exports and a €20 Billion Sector

Medtech Ireland is one of the country’s most remarkable industrial success stories, growing from a modest 75-company cluster in the early 1990s to a sector encompassing more than 500 companies, employing 50,000 people and generating approximately €20 billion in annual exports. Ireland is the second-largest exporter of medical devices in Europe and the largest employer of medtech professionals per capita on the continent. Nine of the world’s top ten medical device companies operate in Ireland, alongside more than 400 homegrown businesses developing everything from cardiovascular stents and orthopaedic implants to respiratory devices and AI-powered diagnostics. This guide covers the scale of the sector, the Galway cluster at its heart, key companies, the regulatory landscape and the trends shaping the future of Irish medtech.

📊 Scale of the Sector

Ireland’s medtech sector has reached a scale that positions it among the top five global medtech hubs. The sector employs 50,000 people directly, with the broader life sciences and health tech ecosystem supporting over 100,000 jobs. Annual exports have reached €20 billion, representing approximately 14% of Ireland’s total exports and making medical devices one of the country’s largest export categories alongside pharmaceuticals and technology.

The sector generates enormous value from highly specialised manufacturing. Ireland produces an estimated 80% of the world’s stents and 75% of global orthopaedic knee devices – extraordinary concentrations for a country of 5.1 million people. Products manufactured in Ireland include cardiovascular devices, orthopaedic implants, contact lenses, respiratory equipment, diagnostic instruments and surgical tools, exported to more than 100 countries worldwide.

Investment activity remains strong. In 2024, Enterprise Ireland reported 89 venture capital deals closed in the life sciences and health tech sectors – the highest number in a decade – valued at €491.3 million in total. Enterprise Ireland was involved in 60 of these deals and was ranked among the top three most active European health tech investors. On a per capita basis, Ireland is number one in Europe for investment in life sciences and health tech companies, a position the country has maintained despite global contraction in venture funding.

🏙️ The Galway Cluster

Galway is the undisputed capital of Irish medtech, frequently described as the Silicon Valley of medical technology. The city and its surrounding region are home to more than 100 medtech companies, creating one of the most concentrated clusters of medical device expertise anywhere in the world. This cluster did not emerge by accident – it is the product of decades of strategic investment, academic excellence, multinational presence and a self-reinforcing ecosystem of talent, suppliers and innovation.

The story begins with Medtronic, which established its first European manufacturing operation in Galway in 1999. The company is operationally led from Minneapolis but is domiciled in Ireland with its registered headquarters in Galway, a structure adopted following its 2015 combination with Covidien. Boston Scientific followed with major manufacturing facilities, and the presence of these anchor companies attracted a dense network of specialist suppliers, contract manufacturers, engineering services firms and startup companies. Today, Galway’s medtech cluster exports more than 4 million heart stents, vascular balloons and other medical devices annually.

University of Galway (formerly NUI Galway) is the academic powerhouse behind much of the cluster’s research capability. The university has focused its research on biomedical engineering science as a priority area since the early 2000s, building world-class interdisciplinary research centres that work closely with industry, healthcare providers and government agencies. CURAM, a Science Foundation Ireland Research Centre for Medical Devices based at University of Galway, represents a unique partnership between academia and industry partners pushing the scientific frontiers in medical device development. Research groups at the university work on cardiovascular disease, cancer biology, orthopaedic disorders, neurodegenerative diseases, biomechanics and biomaterials.

The BioInnovate programme, modelled on Stanford University’s Biodesign programme, fosters needs-driven medical device startups by training fellows to identify unmet clinical needs and develop technology solutions. This approach has produced a pipeline of innovative companies that benefit from proximity to Galway’s multinational manufacturing base and clinical expertise at University Hospital Galway.

🏭 Key Companies

Medtronic is the sector’s anchor company in Ireland, employing approximately 5,000 people with a €5 million, five-year research partnership with University of Galway. The company manufactures a wide range of therapeutic and diagnostic devices. Boston Scientific has invested €100 million in expanding its Galway operations, adding 300 new jobs and 40,000 square feet of new clean room space powered by renewable energy. The facility exports millions of cardiovascular devices annually.

Stryker opened what it described as the largest 3D printing factory of its kind globally at its Cork facility in 2022 – a 156,000 square foot additive manufacturing plant creating 600 high-tech jobs producing specialist orthopaedic implants and devices. Abbott has invested a historic $450 million in a new greenfield facility in Kilkenny that will create 1,000 additional jobs, expanding its Irish workforce to approximately 6,000 – making Abbott one of the largest medtech employers in the country. Zimmer Biomet, Hollister, Cook Medical (with significant operations in Limerick) and Dexcom (which has expanded its continuous glucose monitoring operations) all maintain substantial Irish manufacturing and R&D facilities.

The sector’s strength extends beyond device manufacturing to include a deep supply chain of specialist services. Ireland has developed significant capabilities in contract manufacturing, precision engineering, sterilisation services, cleanroom design, regulatory consulting and quality management. This supporting ecosystem means that companies establishing or expanding in Ireland can access the full range of services needed to bring a medical device from concept through regulatory approval to commercial manufacture, without leaving the country.

Irish-founded medtech companies have also achieved global scale. Aerogen, based in Galway, is the world leader in acute care aerosol drug delivery, with its technology used in hospitals across more than 75 countries. The company’s devices were in high demand during the COVID-19 pandemic for delivering aerosolised medication to ventilated patients. Creganna (now part of TE Connectivity) built a global contract development and manufacturing business from Galway. Neuravi (acquired by Johnson & Johnson’s Cerenovus division) developed stroke treatment devices that have saved lives worldwide. More recent success stories include Neurent Medical, which develops minimally invasive treatments for chronic rhinitis, and CardiacBooster, which received funding from the Disruptive Technologies Innovation Fund.

📜 Regulatory Landscape

The regulatory environment for medical devices has undergone fundamental change with the implementation of the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). These regulations, which replaced the older Medical Device Directives, impose significantly more rigorous requirements for clinical evidence, post-market surveillance, device traceability and manufacturer accountability. The transition has been challenging for the global medtech industry, with extended timelines and resource-intensive compliance processes.

For Irish medtech companies, regulatory expertise has become a competitive differentiator. The country’s concentration of regulatory affairs professionals, notified body experience and proximity to the European regulatory ecosystem means that companies based in Ireland can navigate the MDR and IVDR requirements more efficiently than competitors in less developed regulatory environments. Irish Medtech, the Ibec representative group for the sector, has actively engaged with EU institutions on regulatory implementation, including welcoming the European Commission’s 2025 revision proposal as a critical step for sustained patient access to health technology.

The National Standards Authority of Ireland (NSAI) plays an important role as an EU notified body for medical device conformity assessment. Strong quality management infrastructure, including extensive experience with ISO 13485 (the quality management standard for medical devices), supports the sector’s ability to meet the demands of the new regulatory framework.

🔬 Research and Innovation

Ireland’s medtech research ecosystem is characterised by close collaboration between universities, research centres and industry. Beyond CURAM at University of Galway, other significant research centres include REMEDI (the Regenerative Medicine Institute), which conducts translational research in stem cell biology, and the Tyndall National Institute at University College Cork, which develops sensor and microelectronics technologies with applications in medical devices and health monitoring.

The Disruptive Technologies Innovation Fund (DTIF), a €500 million State-sponsored programme, encourages collaboration between SMEs, large companies and research institutions. To date, DTIF has awarded €298 million to 68 projects in the health and wellbeing sector, making it one of the most significant public funding sources for medtech innovation in Ireland. Enterprise Ireland’s direct investment in health tech companies, combined with programmes like BioInnovate and various accelerators including NovaUCD and Accelerate Green, creates multiple pathways for medtech startups to access funding, mentorship and market opportunities.

🔮 Emerging Trends and the Future

Several trends are shaping the future of Irish medtech. Connected medical devices – wearables, implantables and remote monitoring systems that communicate patient data in real time – represent a convergence of traditional device engineering with digital technology. Ireland’s established strengths in both medical device manufacturing and technology infrastructure position it well for this transition, though it also introduces new challenges around cybersecurity, data privacy and regulatory compliance for software-enabled devices.

Additive manufacturing (3D printing) is transforming how medical devices are designed and produced. Stryker’s Cork facility demonstrates the scale that 3D printing can achieve in medtech, producing patient-specific orthopaedic implants that offer better clinical outcomes than traditionally manufactured alternatives. As the technology matures, more Irish facilities are expected to integrate additive manufacturing into their production capabilities.

Artificial intelligence is increasingly being applied to diagnostics, imaging analysis and treatment planning. Irish companies are developing AI-powered tools that can analyse medical images, predict disease progression and support clinical decision-making. The intersection of AI and medtech creates opportunities for Irish companies to combine their device manufacturing expertise with the country’s growing capabilities in artificial intelligence research and industry.

The sector faces ongoing challenges including skills shortages (with 80% of companies citing talent access as a core concern), rising labour and housing costs, the administrative burden of EU MDR compliance, and global trade uncertainties that affect supply chains and export markets. Business sentiment remains mixed, with companies focused on expansion into new markets and product lines while navigating an uncertain macroeconomic environment. Nevertheless, the fundamental strengths of Ireland’s medtech ecosystem – its talent, research infrastructure, multinational base and entrepreneurial culture – remain robust, and the sector’s trajectory from 75 companies to 500 companies over three decades suggests that the best growth may still be ahead.

Ireland’s medtech sector demonstrates what can be achieved when strategic government policy, academic excellence and private sector investment align around a common opportunity. The journey from a small cluster in the west of Ireland to a €20 billion global export sector is one of the most impressive industrial development stories in modern Europe, and one that continues to evolve as new technologies and clinical needs create fresh opportunities for innovation.